Lilly reassures investors that weight-loss drug demand is strong ...

21 hours ago · Eli Lilly also forecast annual profit largely above Wall Street estimates on Thursday, saying it expects to earn between $22.50 and $24.00 per share on an adjusted …

CouponFollow Extension

$22.50
OFF

Lilly Reassures Investors That Weight-loss Drug Demand Is Strong ...

2 weeks from now

21 hours ago · Eli Lilly also forecast annual profit largely above Wall Street estimates on Thursday, saying it expects to earn between $22.50 and $24.00 per share on an adjusted …

reuters.com

$22.50
OFF

Lilly Forecasts 2025 Profit Largely Above Estimates On Weight-Loss …

2 weeks from now

1 day ago · On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting a profit of $22.86 per share, according to …

usnews.com

$58
OFF

Eli Lilly Adjusted Profit Tops Estimates As Weight-Loss

2 weeks from now

20 hours ago · Eli Lilly said it expects 2025 revenue between $58.0 to $61.0 billion, with EPS from $22.05 to $23.55, and adjusted EPS of $22.50 to $24.00. Those ranges are largely in line with …

investopedia.com

$800
OFF

Eli Lilly Expects To Beat Profit Forecasts On Obesity Drug Demand

2 weeks from now

18 hours ago · Eli Lilly, which has a market capitalisation of $800bn, has said that excess inventory hit sales and profits for its weight-loss drugs in the last two quarters of 2024.

ft.com

$45
OFF

Lilly Provides Update On 2024 Revenue Guidance, Announces 2025 …

2 weeks from now

Jan 14, 2025 · 2024 revenue is expected to be approximately $45.0 billion for the full year, $4.0 billion above the midpoint of first-time 2024 financial guidance. Q4 2024 revenue is expected …

lilly.com

$1.91
OFF

Lilly Forecasts 2025 Profit Largely Above Estimates On Weight-loss …

2 weeks from now

21 hours ago · Zepbound, its weight-loss treatment, reported revenue of $1.91 billion, below the $2.03 billion analysts were expecting. Lilly last month said it expected fourth-quarter sales of …

investing.com

32%
OFF

Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5

2 weeks from now

Jan 14, 2025 · Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and Zepbound. The 2025 outlook forecasts up to $61 billion.

benzinga.com

$620
OFF

Lilly's Growth In Diabetes And Obesity, And Strong Oncology And ...

2 weeks from now

11 hours ago · Lilly's strong leadership in weight-loss drugs should ... We are raising our Eli Lilly fair value estimate to $620 from $580, after our adjusting our long-term earnings growth rate …

morningstar.com

$22.50
OFF

Eli Lilly Fourth-Quarter Sales Meet Views; Reiterates 2025 Revenue …

2 weeks from now

14 hours ago · Lilly forecasts 2025 profit largely above estimates on weight-loss drug strength 06:55am: RE ... $22.50 - $24.00 06:50am: MT Eli Lilly forecasts 2025 profit largely above …

marketscreener.com

$58
OFF

Eli Lilly Tumbles On Lowered Guidance As Weight-Loss Drug Sales …

2 weeks from now

Jan 14, 2025 · Eli Lilly said it expects 2025 revenue of $58 billion to $61 billion vs. the consensus estimate of $58.5 billion. The company reports full fourth-quarter and 2024 financial results on …

investors.com

FAQs about Lilly reassures investors that weight-loss drug demand is strong ... Coupon?

Why is Eli Lilly forecasting a profit above Wall Street estimates?

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, as it prepares to launch its popular diabetes and weight-loss treatments in new markets. The forecast comes weeks after the drugmaker stunned investors with weaker-than-expected sales for its weight-loss drug Zepbound for the second straight quarter. ...

How much will Lilly make in 2025?

Lilly has previously forecast total sales to be between $58 billion and $61 billion in 2025 and expects to launch its popular drug Mounjaro in new markets, including China, India, Brazil and Mexico for both diabetes and weight-loss patients. On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. ...

How big is the weight-loss market?

Lilly's Zepbound and Novo's Wegovy dominate a market for weight-loss treatments that analysts expect to be a $150 billion market by the early 2030s. Both the drugmakers have seen rapid growth in recent years, fueled by investor interest in their weight-loss and diabetes treatments. ...

Will Lilly promote zepbound this year?

Investors and analysts expect Lilly to share details on how it plans to promote Zepbound this year in a bid to take more market share from Wegovy, an older, more established drug. Lilly began advertising the drug in November and has previously blamed physical and financial constraints at wholesalers for the sales miss. ...